Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upjohn's Rogaine self-selection studies praised by NDAC member.

This article was originally published in The Tan Sheet

Executive Summary

PHARMACIA & UPJOHN ROGAINE SELF-SELECTION STUDIES "FAIRLY GOOD," FDA Nonprescription Drugs Advisory Committee member Ralph D'Agostino, PhD, Boston University, said at a Nov. 17 joint meeting of NDAC and the Dermatologic and Ophthalmic Drugs Advisory Committee. Commenting on whether the company was able to show that consumers can accurately determine if their hair loss could be treated by OTC Rogaine given the information provided on the product label, D'Agostino described the firm's studies as "fairly good" and the results "pretty respectable."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel